Biotech The biotech scorecard for the first quarter: 14 stock-moving events to watch By Adam Feuerstein @adamfeuerstein
January 3, 2020
Ryan Pierse/Getty Images
H ere is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the first quarter.
It’s rare to include a new drug submission to the Food and Drug Administration in the quarterly scorecard. With that said, any development regarding Biogen’s ( BIIB ) controversial Alzheimer’s drug aducanumab is significant enough to matter. Biogen has told investors that it will complete the aducanumab filing to the FDA in “early 2020” — which sounds like the first quarter.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTED Log In | Learn More What is it? STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day Online intelligence briefings Frequent opportunities to engage with veteran beat reporters and industry experts Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. GET STARTED
Also in Industry News
CDC Coronavirus Testing Decision Likely to Haunt US for Months to Come
Cannabidiol helps fight antibiotic-resistant bacteria
Changes in surface sugarlike molecules help cancer cells to spread